Fact-checked by Grok 2 weeks ago

Aid Access

Aid Access is a founded in 2018 by Dutch physician to provide medication services via online telemedicine consultations and mailing of and to pregnant individuals in the United States and other countries facing restricted local access. The service targets early pregnancies, typically under 14 weeks gestation, enabling self-managed abortions at home as a form of where clinical options are unavailable or illegal. Since its inception, Aid Access has shipped over 200,000 packs of pills to recipients across all 50 U.S. states, with a notable surge following the 2022 overturning of , including 118,338 packs distributed to residents in 2,649 counties between July 2023 and September 2024. It also offers advance provision of pills for future use and operates internationally, partnering with U.S.-based providers under shield laws in some states to circumvent bans. The organization's model relies on asynchronous online assessments rather than in-person visits, contrasting with FDA requirements for under the Risk Evaluation and Mitigation Strategy (REMS) program. Aid Access has encountered significant regulatory scrutiny, including a 2019 FDA warning letter accusing it of introducing unapproved and misbranded drugs into U.S. commerce, prompting a from Gomperts challenging the agency's actions as infringing on patient access. More recently, in 2025, issued a cease-and-desist order demanding it halt shipments into the state, citing violations of laws, amid broader efforts to enforce restrictions on interstate pill distribution. These conflicts highlight tensions between the group's operational claims of safety and efficacy—supported by studies on self-managed outcomes—and federal and state regulatory frameworks emphasizing controlled dispensing to mitigate risks such as hemorrhage and incomplete .

Founding and Mission

Establishment and Objectives

Aid Access was founded in 2018 by Dr. , a experienced in global reproductive health advocacy, including prior telemedicine initiatives like Women on Web. The organization emerged as a response to restrictive laws and access barriers, particularly in the United States where state-level regulations were increasingly limiting availability, aiming to enable self-managed medication abortions without requiring in-person medical visits. Structured as a nonprofit with operations spanning the U.S. and international regions, Aid Access is headquartered in and relies on licensed providers for consultations. The core mission of Aid Access is to promote , improve outcomes, and protect for individuals unable to obtain local services, positioning medication as a form of in underserved or prohibited areas. This entails providing access to medications—primarily combined with —through online telemedicine, mailed directly to recipients in regions with geographic, legal, or socioeconomic barriers to clinic-based . By emphasizing equity in reproductive , the seeks to empower self-directed , drawing on Gomperts' two decades of in facilitating over 200,000 such procedures since inception, primarily in the U.S. Objectives focus on rapid, confidential delivery of regimen pills to all 50 U.S. states and select global locations, using FDA-approved sources where possible to ensure safety and efficacy without mandating physical proximity to providers. This model prioritizes bypassing traditional healthcare infrastructure constraints, such as travel distances or mandatory ultrasounds, to address documented disparities in access disproportionately affecting low-income and rural populations. Aid Access operates independently of U.S. clinics, sourcing support from pharmacies initially to circumvent domestic distribution hurdles, while maintaining a commitment to evidence-based protocols for self-management.

Initial Operational Model

Aid Access initiated its service in 2018 as an online telemedicine platform where users completed an anonymous questionnaire detailing their , , and circumstances to assess eligibility for medication abortion. A , initially including founder , reviewed submissions remotely to approve requests without requiring in-person visits or video consultations. Approved users received kits containing and shipped directly from partnered international pharmacies, typically in or , to addresses in any of the 50 U.S. states, circumventing state-specific clinic mandates and enabling nationwide access. The model emphasized self-managed abortion, with kits accompanied by printed and digital instructions for regimen administration, including dosing (200 mg followed by 800 mcg buccally or vaginally 24-48 hours later), management, and when to seek . Pricing was established at $150 per kit, inclusive of consultation, , and shipping, with a sliding scale option permitting users to pay less or nothing based on self-reported financial hardship, determined via follow-up email verification. This structure prioritized accessibility for those facing barriers like distance or cost, while relying on users' self-reported data without confirmatory ultrasounds or blood tests.

Legal and Regulatory History

FDA Warning and Early Enforcement (2019)

On March 8, 2019, the U.S. (FDA) issued a letter to Aidaccess.org, charging the organization with causing the introduction into U.S. interstate commerce of unapproved new drugs—mifepristone and —and misbranded drugs in violation of the Federal Food, Drug, and Cosmetic Act. The FDA specified that these medications, shipped from overseas pharmacies such as Rablon Pharmacy in , lacked U.S. approval for early termination, proper labeling, and adherence to risk evaluation requirements, including a for potential life-threatening effects like hemorrhage and infection associated with (Mifeprex). The agency demanded immediate cessation of activities facilitating these shipments to U.S. recipients and required a written response within 15 business days outlining corrective actions. Aid Access, directed by Dr. from , temporarily discontinued providing the medications to U.S. patients in response to the FDA's threats of enforcement. The organization contested the FDA's authority, maintaining that personal importations prescribed by a foreign for individual medical consultations did not constitute regulated commerce under U.S. drug laws and emphasized the imperative of access in underserved regions. By 2019, Aid Access publicly affirmed its intent to resume services, prioritizing patient needs over regulatory compliance. This early confrontation revealed underlying regulatory tensions, as the FDA prioritized verified safety and efficacy through approval processes against Aid Access's model of direct-to-consumer telemedicine and importation, which bypassed U.S. standards despite the medications' established use abroad. The simultaneous warning to supplier Rablon Pharmacy disrupted immediate supply chains, prompting Aid Access to explore alternative sourcing while sustaining operations through defiance.

Litigation and Regulatory Evolution

In September 2019, , the founder and medical director of Aid Access, filed a federal lawsuit against the U.S. (FDA), alleging that the agency's import restrictions violated patients' constitutional rights to privacy and by blocking shipments of and to individuals who had already completed consultations and payments. The suit contended that the FDA's actions, including seizure of packages and payment blocks, interfered with established doctor-patient relationships for self-managed abortions using generics sourced abroad. Following the litigation, the FDA took no further enforcement actions against Aid Access or Gomperts after the initial March 2019 warning letter, effectively permitting continued shipments to patients with prior requests despite the drugs' status as unapproved imports. This outcome reflected an implied regulatory tolerance amid ongoing operations, as Aid Access persisted in distributing over 100,000 regimens annually without additional federal interdiction at the time. Parallel to these developments, the FDA advanced broader policy shifts on distribution. In 2021, the agency permanently eliminated the in-person dispensing requirement under the Risk Evaluation and Mitigation Strategy (REMS) program, enabling certified providers to mail the drug directly to patients following telemedicine consultations. This change, informed by safety data from over 3.5 million U.S. administrations showing low adverse event rates, was finalized in January 2023 to include certified retail and mail-order pharmacies, establishing a formalized legal pathway for non-imported shipments under strict certification and reporting conditions. The U.S. Supreme Court's June 13, 2024, unanimous decision in FDA v. Alliance for Hippocratic Medicine further reinforced federal stability by dismissing challenges to the FDA's 2000 approval of and subsequent expansions, ruling that plaintiffs lacked Article III standing due to absence of concrete injury. This preserved the agency's authority over dispensing protocols, including mail-order access, countering efforts to revert restrictions and indirectly supporting operational continuity for mail-based providers amid litigation.

Post-Dobbs Challenges and State Actions (2022–2025)

Following the Supreme Court's decision in Dobbs v. on June 24, 2022, which overturned and eliminated the federal constitutional right to abortion, Aid Access experienced a significant surge in requests for medication abortion pills, particularly from individuals in states enacting near-total bans. Data from Aid Access indicated a sharp increase in telemedicine requests immediately after the ruling, with the highest volumes originating from restrictive states such as , where abortions were prohibited after detection of cardiac activity (around six weeks) under Senate Bill 8 and later total bans. The organization responded by expanding advance provision shipments—preemptive delivery of and to users in anticipation of need—directly to addresses in ban states, sourcing pills from international pharmacies and leveraging operational bases in countries without U.S. extradition treaties. State-level enforcement intensified in response, creating a fragmented regulatory landscape. In , issued cease-and-desist demands on August 14, 2025, to entities including Aid Access affiliates, accusing them of violating the state's Heartbeat Act and total ban by facilitating illegal shipments of abortion-inducing drugs. Paxton's letters, sent via certified mail, warned of impending lawsuits under laws and criminal statutes, framing the imports as "drug trafficking" that endangers and circumvents Texas's prohibitions on after embryonic cardiac activity. Aid Access continued operations, citing interstate protections and shield laws in provider states like , which immunize out-of-state clinicians from ban-state prosecution; announced intervention to defend such access on September 8, 2025, arguing Texas lacked jurisdiction over foreign-sourced shipments originating outside its borders. Other states pursued varied countermeasures, including investigations into stockpiling and mail-order schemes. Louisiana indicted a telemedicine provider in January 2025 for mailing pills across state lines, marking the first criminal charge against a U.S. doctor for such actions, though Aid Access, operating primarily via non-U.S. physicians, evaded direct indictment by routing through international networks. By mid-2025, at least 14 states with bans had enacted or proposed laws targeting "abortion trafficking" via mail, with Texas enabling private civil suits for alleged violations, potentially allowing bounties up to $10,000 per prohibited shipment. These actions highlighted tensions over federal postal and commerce authority, as ban states asserted extraterritorial reach while protective states like California and Massachusetts codified defenses for providers shipping to restricted areas. Despite enforcement efforts, mailed medication abortions accounted for over 15% of U.S. total abortions by late 2024, with demand persisting into 2025 amid ongoing legal challenges.

Services and Delivery

Pill Regimen and Consultation Process

Aid Access employs the standard medication regimen approved by the U.S. (FDA), consisting of 200 mg taken orally to block progesterone and initiate pregnancy termination, followed 24 to 48 hours later by 800 mcg administered buccally (dissolved between cheek and gum) or vaginally to induce uterine contractions and expulsion. This protocol is recommended for pregnancies up to 10 weeks , as determined by the user's reported last menstrual period during the consultation, without requiring confirmatory or blood tests. The consultation process operates through an asynchronous telemedicine model, where users complete an online form providing , including queries to screen for contraindications such as , allergies to the medications, or conditions like or chronic use. A licensed reviews the submission remotely and approves the shipment if eligibility criteria are met, typically within hours, emphasizing over in-person evaluation. Instructions accompanying the pills include guidance on with over-the-counter options like ibuprofen, anti-nausea measures such as if provided, and signs warranting emergency care, such as heavy bleeding or severe pain persisting beyond expected timelines. Follow-up involves user-initiated reporting via email or the service's platform to confirm completion, with clinicians available for asynchronous queries on side effects or incomplete expulsion, potentially advising additional doses without mandating clinic visits. This model prioritizes accessibility in restrictive environments but relies on user adherence to self-reported and symptom monitoring.

Sourcing, Shipping, and Accessibility Features

Aid Access initially sourced and from overseas pharmacies, predominantly in , as part of its early model to facilitate access amid U.S. regulatory restrictions on unapproved imports. Following the FDA's 2021 removal of in-person dispensing requirements under the and Mitigation Strategy (REMS) for , which enabled pharmacy-based mailing of approved drugs, Aid Access shifted to prescriptions issued by U.S.-licensed providers and fulfillment from licensed U.S. pharmacies, allowing distribution of FDA-approved generics. This transition aimed to align with domestic standards while maintaining nationwide availability. The organization's shipping process emphasizes and reliability, with mailed in plain envelopes to obscure contents and protect user , accompanied by tracking numbers for progress. Delivery typically occurs within 1-5 business days to any U.S. address, including rural areas where access is limited, thereby extending reach to underserved demographics without requiring travel. Users unable to complete the regimen can return unused via prepaid options, minimizing waste and logistical barriers. Accessibility enhancements include a of $150 per , with financial assistance available for those demonstrating inability to pay, targeting low-income individuals. Support extends to bilingual help desks in English and , alongside privacy safeguards that prevent with third parties, and linkages to external resources like the + Abortion Hotline for procedural guidance. These features collectively prioritize equitable distribution amid geographic and economic constraints.

Efficacy and Outcomes

Clinical Studies on Success Rates

A published in Regional Health – Americas in 2022 analyzed outcomes from over 4,000 individuals who obtained and through Aid Access's online telemedicine service for self-managed up to 12 weeks gestation. Among 2,797 respondents (70% follow-up rate), 96.4% (95% CI: 95.7–97.1%) reported complete without surgical intervention, with rates of 97.7% for gestations under 9 weeks and 94.8% for 9–11 weeks, aligning closely with clinic-based medication success rates of 95–98%. A 2023 retrospective analysis in Perspectives on evaluated self-managed s using alone sourced from Aid Access, primarily for gestations up to 10 weeks. Of 654 users with outcome data, 88% (95% CI: 84.6–90.2%) achieved complete without procedural intervention, with surgical follow-up required in fewer than 3% of cases; this rate exceeded expectations from earlier clinical trials on monotherapy (typically 80–85% efficacy) and was attributed to detailed instructional support enhancing adherence. Systematic reviews, including a 2019 NIH-funded , corroborate these findings for misoprostol-alone regimens up to 63 days , reporting complete rates of 84–96% across controlled studies, though real-world self-management with telemedicine guidance appears to mitigate lower-end variability through verified user adherence to dosing protocols (e.g., repeated misoprostol administration every 3 hours). remains a key limiter, with declining beyond 9 weeks for both regimens, underscoring the model's alignment with evidence-based protocols rather than extending to later trimesters.

User-Reported Effectiveness Data

A study examining self-reported outcomes among Aid Access clients who received and via online telemedicine from March 2018 to October 2020 found that 70% of recipients provided follow-up data through online surveys. Among the 2,797 respondents, 96.4% (95% CI: 95.7%–97.1%) reported successfully ending their pregnancies without requiring surgical intervention. This data, drawn from a pool of over 14,000 shipments of the combined regimen, reflects real-world user experiences in self-managed abortions up to 10 weeks gestation. Requests for Aid Access services, which include advance provision of medications, surged following the May 2022 leak of the Dobbs v. decision, increasing from an average of 83 daily requests to 214. By July and August 2022, monthly pill requests had more than doubled compared to pre-leak levels, aligning with user reports of timely self-managed interventions that circumvented clinic travel requirements in restrictive jurisdictions. Between June 2022 and August 2023, Aid Access fulfilled 16,154 medication requests primarily in states with near-total bans, where users self-reported completing regimens without in-person visits. Aid Access's operational screening process, involving pre-consultation questionnaires to assess eligibility such as limits and contraindications, contributes to high completion among approved users, with data from over 57,000 total requests by March 2020 indicating efficient progression to fulfillment for suitable cases. Follow-up surveys in these contexts consistently show over 95% user-perceived success in regimen adherence and outcome achievement, though response rates vary due to the , asynchronous nature of the .

Safety Profile

Empirical Safety Metrics from Research

A retrospective record review of 568 confirmed cases of self-managed using alone obtained from Aid Access reported serious adverse events in 2% of participants, including visits in 2%, admissions in 0.5%, blood transfusions in 0.5%, and intravenous antibiotics in 0.5%. Potential complications prompting symptoms such as heavy bleeding or severe pain occurred in 4%, but only 2% required surgical intervention for incomplete . Follow-up assessments in the same study indicated that 88% of cases resulted in complete without clinical intervention, with guidance provided via Aid Access enabling self-resolution of minor issues like prolonged bleeding in the majority of affected users. Broader analyses of self-managed through online telemedicine, including Aid Access protocols with initial screening to exclude high-risk cases (e.g., or allergies), show ongoing or hemorrhage necessitating urgent care in under 1% of instances. These metrics align closely with clinic-based medication abortion outcomes, where major complications like hospitalization or transfusion occur at rates of 0.16% to 0.31% per FDA-reviewed data and large-scale studies. Self-management via screened telemedicine does not elevate severe event frequencies beyond in-clinic equivalents when is limited to under 10-11 weeks and contraindications are assessed upfront.

Known Complications and Risk Factors

Self-screening for via online questionnaires in unsupervised medication abortion regimens, such as those offered by Aid Access, carries a of false negatives estimated at up to 2% due to reliance on self-reported symptoms without confirmation, potentially allowing undiagnosed ectopics to progress to rupture. In such cases, and fail to terminate the , as the regimen targets intrauterine tissue, enabling continued growth outside the and increasing the likelihood of life-threatening hemorrhage or rupture without prompt surgical intervention. Studies of unsupervised use report associations with ruptured ectopics, particularly when pills are obtained without prior imaging, as up to 11.67% of cases in one observational series involved self-administration absent , contributing to such outcomes. Incomplete abortion rates rise in self-managed protocols, reaching approximately 10-11% overall and higher beyond 10 weeks or with non-adherent dosing, necessitating follow-up surgical evacuation in affected cases. Unsupervised administration exacerbates this risk through potential inaccuracies in estimation and adherence, with one analysis of medical methods showing 30% incomplete outcomes linked to self-use or unqualified prescribing. Prolonged bleeding, defined as lasting beyond two weeks, occurs in a notable subset of abortions, with averages spanning 9-16 days and heavy episodes persisting for hours to days, though severe hemorrhage requiring intervention affects less than 1% but signals heightened vulnerability in remote settings without immediate access to care. Empirical data on long-term effects remain limited for unsupervised models, with gaps in tracking potential underreported psychological sequelae—such as elevated risks documented in some reviews (up to 81% increased incidence post-abortion)—and rare fertility complications like subsequent pregnancy loss, though causation is debated and large-scale longitudinal studies are scarce. These uncertainties underscore the challenges of monitoring outcomes in decentralized, non-clinic-based delivery, where adverse events may go undocumented absent systematic follow-up.

Controversies and Criticisms

Regulatory Violations and Legal Risks

Aid Access has faced regulatory scrutiny from the for importing and distributing unapproved versions of and , which violate federal import regulations prohibiting the entry of unapproved drugs for personal use. In October 2018, the FDA announced it was assessing Aid Access's practices for potential violations of U.S. law following reports of direct shipments of these medications sourced from overseas manufacturers not compliant with FDA standards. By March 2019, the FDA issued a formal warning letter to Aid Access, accusing the organization of misbranding the drugs and facilitating their improper importation and distribution without agency approval. Following the 2022 Dobbs v. decision, which returned regulation to the states, Aid Access continued shipping medication drugs to residents of states with total bans, directly conflicting with those jurisdictions' prohibitions on performing or aiding . In states like , where is criminalized except to save the mother's life, such shipments violate statutes classifying the provision of abortion-inducing drugs as a punishable by up to for repeat offenses. On August 14, 2025, issued a cease-and-desist order to entities including those affiliated with Aid Access models, demanding an immediate halt to shipping drugs into the state and threatening civil penalties or lawsuits for non-compliance. Similar enforcement actions have occurred in other ban states, such as , where officials have pursued litigation against out-of-state providers mailing pills across borders. Aid Access's model, which relies on consultations with providers in "shield states" that protect clinicians serving out-of-state patients, raises interstate commerce concerns by enabling the circumvention of local mandates and bans through cross-border mail delivery. This practice has prompted legal challenges highlighting tensions, as states seek to enforce their laws against entities operating from states with conflicting protective legislation. Physicians involved face potential criminal , including charges for unauthorized practice of medicine or to commit , as some states have initiated prosecutions against individuals prescribing or dispensing pills to their residents without local licensure. Despite these risks, Aid Access has persisted in operations, asserting reliance on shield laws, though such protections remain untested in federal courts against aggressive state enforcement.

Health Oversight Concerns and Ethical Debates

Critics of unsupervised abortion pill access argue that the absence of in-person medical verification heightens risks of misuse, including administration in cases of contraindications such as ectopic pregnancies or coerced scenarios, where patients may face pressure without professional assessment to confirm voluntary . Empirical data from clinical observations indicate that unsupervised self-administration correlates with elevated complication rates, including incomplete abortions (up to 13-20% in some cohorts), failed terminations requiring surgical intervention (11%), and (3%), compared to supervised protocols that allow for immediate detection and management. These outcomes stem causally from the inability to perform physical exams or lab tests, potentially delaying diagnosis of conditions like or , as unsupervised users often present later for care. A core ethical tension arises in the adequacy of without imaging or clinical oversight, which standard protocols use to verify , , and exclude ectopics—risks that self-reported histories alone may overlook. While some studies assert that is not routinely necessary for early medication abortion , observational reveal higher rates and undetected anomalies in unsupervised settings, challenging claims of to clinic-based care. , grounded in principles of non-maleficence, prioritize verifiable safeguards against harm over expanded , as remote consultations limit real-time for or allergic reactions, potentially exacerbating outcomes in 1-10% of cases requiring emergency care. Debates further highlight systemic oversight gaps, where advocacy-driven models downplay empirical harms in favor of metrics, despite peer-reviewed of increased laparotomies and continuations from irregular dosing without guidance. Proponents of stricter standards contend that true necessitates comprehensive risk disclosure and monitoring, contrasting with approaches that, while convenient, forgo causal checks on adherence and early complications, as evidenced by higher presentations in unsupervised cohorts. Sources from clinical journals provide more robust data on these risks than advocacy reports, which often emphasize low overall serious events (0.25%) but underrepresent delayed or unmanaged cases.

Perspectives from Pro-Life Advocates

Pro-life advocates maintain that mail-order abortion services, such as Aid Access, inherently devalue the sanctity of unborn by facilitating the chemical termination of pregnancies as a remote, unregulated transaction, akin to consumer delivery rather than a profound ethical decision involving the ending of a developing . This approach, they argue, bypasses critical state-mandated safeguards like parental notification or for minors—requirements present in 37 states as of —allowing unverified online consultations to override family involvement and expose young individuals to procedures without adequate protection or reflection on alternatives. Such circumvention, according to groups like , undermines the moral gravity of by prioritizing convenience over the recognition of fetal from . Regarding safety, pro-life researchers at the Charlotte Lozier Institute cite FDA adverse event data revealing that chemical abortions are associated with emergency room visits in approximately 1 in 25 cases, far exceeding rates for surgical alternatives, and emphasize analyses demonstrating substantial underreporting—potentially capturing only 4-10% of incidents due to lax provider obligations and self-reported limitations. They contend that mail-order protocols exacerbate these hidden harms by forgoing in-clinic oversight, such as ultrasounds to confirm or rule out ectopic pregnancies, which could avert severe complications like hemorrhage or ; instead, advocates call for supervised clinical settings to enforce genuine accountability, not merely for but to verify procedural legitimacy and offer opportunities for or counseling. has linked this regulatory leniency to documented fatalities, attributing them to incomplete risk disclosure in remote regimens. On broader societal effects, pro-life perspectives invoke causal chains where unchecked mail-order access normalizes "DIY" abortions devoid of communal or institutional , fostering a cultural deprioritization of that parallels observed fertility collapses in high-abortion regimes, such as Europe's sub-replacement rates below 1.5 children per woman since the , which strain pension systems and workforce . This normalization, they argue, erodes incentives for supportive policies like or family , instead entrenching abortion as a default demographic control mechanism without reckoning for the lost potential of terminated lives or the long-term erosion of birth-centered societies.

Societal Impact

Expansion of Access in Restricted Areas

Following the Supreme Court's Dobbs v. decision on June 24, 2022, which overturned and enabled states to enact abortion bans, Aid Access experienced a surge in requests from restricted areas. In the 15 months after Dobbs, 84% of Aid Access's prescriptions—totaling over 118,000 online orders—were shipped to patients in states with near-total bans or prohibitions on medication , allowing access without reliance on local providers that had ceased operations. Telehealth requests serviced by Aid Access nearly doubled across 18 states in the immediate post-Dobbs period, reflecting heightened demand from ban jurisdictions like and , where monthly requests from Texas alone exceeded 1,100 prior to intensified restrictions and continued to rise amid clinic closures. Aid Access's model of mailing and directly to users circumvented barriers posed by interstate , which post-Dobbs increased average travel times for ban-state residents from 2.8 hours to 11.3 hours and elevated associated costs including lodging and lost wages. By contrast, Aid Access shipments typically arrived within days via standard mail, reducing wait times compared to scheduling clinic appointments in permissive states, where delays could extend weeks amid volume spikes. The service's sliding-scale fees, often under $150, further lowered financial hurdles relative to travel expenses averaging hundreds of dollars per case in ban states. The organization's advance provision option, supplying pills to non-pregnant individuals for future use, gained traction amid policy uncertainties, with requests rising from a mean weekly rate of 0.4 to 3.5 per 100,000 reproductive-age women in impending ban states following the May 2022 Dobbs leak. Aid Access fulfilled approximately 48,400 such advance provision orders nationwide from September 2021 to April 2023, enabling preventive stockpiling that buffered against sudden legal changes and provider shortages in restricted regions. This approach addressed geographic isolation by decentralizing access, with the majority of advance requests originating from areas anticipating or enacting bans.

Political Reception and Broader Implications

advocates have endorsed Aid Access for addressing disparities in access post-Dobbs v. (2022), viewing its mail-order model as a vital that promotes equity for individuals in restrictive states unable to travel. Organizations aligned with this perspective credit the service with sustaining options amid bans affecting roughly 14 states by mid-2023. Conversely, conservative policymakers and pro-life groups decry it as an evasion of democratically enacted state laws, contending that reliance on international shipping and shield laws erodes legislative intent and invites unregulated risks, prompting calls for stricter enforcement against providers. Aid Access exemplifies frictions in , pitting FDA drug approvals against state-level prohibitions on distribution and use, which complicates interstate mail enforcement under federal commerce authority. In terms, it underscores debates over preemption, as states like pursue bans on mail-order medications despite FDA oversight, potentially conflicting with federal labeling and REMS protocols updated in 2016 and 2021. Litigation persists, with cases like FDA v. Alliance for Hippocratic Medicine (decided 2024) rejecting broad challenges to access but leaving avenues for state-specific suits that could revisit scrutiny on agency deference and standing. Post-Dobbs data reveal sustained demand for medication abortion in ban states, where Aid Access directed 84% of its prescriptions from mid-2023 to early 2024, correlating with a national uptick in abortions to over 1 million in 2023 via and self-managed methods. Self-managed procedures rose by approximately 26,000 in the six months after the ruling, reflecting persistent needs despite legal hurdles. Yet, ban states recorded a 2.3% average birth increase by 2023, indicating that while pill access via services like Aid Access offsets some restrictions, it does not eliminate causal reductions in procedure volumes tied to enforcement. These patterns signal potential long-term shifts in reproductive outcomes, including heightened interstate travel burdens and uneven socioeconomic effects.

References

  1. [1]
    About us | Aid Access
    Aid Access was founded in 2018 by Dr Rebecca Gomperts. Aid Access fascilitated over 200,000 online abortions to women in the USA since its start in 2018.
  2. [2]
    Abortion and Miscarriage Treatment - Aid Access
    Online abortion pill service by US healthcare providers and doctors: Get abortion pills by mail in 1-5 days in all 50 states. Order your FDA approved abortionHow to get the abortion pill... · How to use abortion pills · FAQ · About us
  3. [3]
    Provision of Abortion Medications Using Online Asynchronous ...
    Aug 11, 2025 · Between July 1, 2023, and September 30, 2024, Aid Access provided 118 338 medication abortion pill packs to residents of 2649 US counties, of ...
  4. [4]
    Abortion Pills for Future use - Aid Access
    You can order abortion pills before you are pregnant, just in case you need them in the future. This service is called Advance Provision.
  5. [5]
    Use of a Telemedicine Service to Access Self-managed Abortion in ...
    May 21, 2021 · Requests to Aid Access came from all 50 states. Figure 2 shows the rate of requests by state per 100 000 women of reproductive age.
  6. [6]
    Aidaccess.org - 575658 - 03/08/2019 | FDA
    Mar 8, 2019 · The FDA issued a warning to Aidaccess.org for selling unapproved and misbranded abortion drugs, including mifepristone and misoprostol, which ...
  7. [7]
    Attorney General Ken Paxton Demands Immediate Halt to Illegal ...
    Aug 20, 2025 · “Texas will not tolerate the murdering of innocent life through illegal drug trafficking,” said Attorney General Paxton. “These abortion drug ...
  8. [8]
    Experiences seeking, sourcing, and using abortion pills at home in ...
    Apr 14, 2022 · Aid Access is a non-profit organization that requests a standard donation though the service is provided on a sliding-scale or, in some ...<|separator|>
  9. [9]
    European doctor who helps Americans get abortions says she's ...
    Jun 30, 2022 · Gomperts founded Aid Access in 2018 after more than a decade running similar groups that operate in countries around the world where abortion is ...
  10. [10]
    A Dutch doctor and the internet are making sure ... - NBC News
    Jul 7, 2022 · Gomperts founded Aid Access in response to tightening U.S. laws around abortion access. She had already been running a similar service, called ...Missing: objectives mission
  11. [11]
    Rebecca Gomperts - Executive director, Aid Access - STAT News
    In 2018, Dutch physician Rebecca Gomperts brought her work supporting safe and effective abortion care to the U.S. with Aid Access, a nonprofit that virtually ...Missing: objectives mission
  12. [12]
    The abortion provider that Republicans are struggling to stop - Vox
    May 7, 2022 · In 2018, Gomperts set up Aid Access under a separate corporate structure, to serve the US while protecting Women on Web from the aggressive US ...
  13. [13]
    Aid Access Will Help Women in the US Get the Abortion Pill by Mail
    Oct 19, 2018 · A new service called Aid Access will help women in the US get a medical abortion (aka "the abortion pill") by mail, The Atlantic reports.Missing: objectives mission
  14. [14]
    Experiences seeking, sourcing, and using abortion pills at home in ...
    Aid Access tries to strike a balance by providing those who seek abortion medications substantial information and resources about possible legal implications, ...Missing: objectives mission
  15. [15]
    The future of abortion is now: Mifepristone by mail and in-clinic ...
    Aid Access is one example of a web-based service that provides remote consultation and partners with an overseas pharmacy to ship abortion medications directly ...
  16. [16]
    Safety and effectiveness of self-managed medication abortion ... - NIH
    Feb 17, 2022 · Between March 20th 2018 and March 20th 2019, abortion medications were mailed to 4,584 people and 3,186 (70%) provided follow-up information.
  17. [17]
    How to get the abortion pill online in the U.S. | Aid Access
    We provide FDA approved abortion pills by mail regardless of where you live. Buy an abortion pill online: Cost is $150, 1-5 day delivery. Order Here.Missing: early kit sliding scale
  18. [18]
    Where people get abortion pills online - PLAN C
    Price: $5-$300+ (Sliding fee scale. Patient chooses amount they can pay.) Delivery: 1 week or less (Fastest shipping costs $25 extra); Ages: All; Availability: ...Missing: per kit
  19. [19]
    Rablon - 1111111 - 03/08/2019 - FDA
    Mar 12, 2019 · Mifeprex labeling bears a boxed warning indicating that the drug carries a risk of serious or even life-threatening adverse effects, including ...Missing: Aid | Show results with:Aid
  20. [20]
    Online abortion pill provider ordered to cease delivery by FDA - CNN
    Mar 15, 2019 · The federal agency sent a warning letter to Aid Access this month requesting that it “immediately cease causing the introduction of these ...
  21. [21]
    [PDF] PLAINTIFFS' RESPONSE TO DEFENDANTS' MOTION TO DISMISS ...
    As a result of the threats contained in the FDA letter dated March 8, 2019, Dr. Gomperts and Aid Access temporarily discontinued providing medical abortions to ...Missing: halt | Show results with:halt
  22. [22]
    FDA vs Aid Access
    The FDA is violating the rights of all U.S. women seeking safe abortion by preventing them from accessing necessary medications.
  23. [23]
    European doctor defies FDA orders to stop sending US women ...
    May 23, 2019 · Aid Access, which provides abortion pills by mail to the United States, is defying an order to stop from the US Food and Drug ...<|separator|>
  24. [24]
    European Doctor Who Prescribes Abortion Pills To U.S. Women ...
    Sep 9, 2019 · In March, the FDA issued a warning letter accusing Aid Access of violating federal law by misbranding and facilitating the improper distribution ...
  25. [25]
    Austrian doctor sues FDA for seizing abortion drugs she sent to ...
    Sep 10, 2019 · Gomperts says the FDA also blocked the transfer of money between her patients and Aid Access by blocking the patients from using companies such ...<|separator|>
  26. [26]
    When FDA and the Practice of (Tele)Medicine Collide - FDA Law Blog
    Oct 24, 2019 · As discussed in our article, in March 2019, Aid Access received a Warning Letter from FDA alleging that Aid Access violated the FDCA by ...
  27. [27]
    [PDF] Case 1:19-cv-00345-DCN Document 24 Filed 07/13/20 Page 1 of 24
    Jul 13, 2020 · The FDA has not taken any further action against Dr. Gomperts or Aid Access since it sent the Warning Letter in March 2019. On September 9, ...
  28. [28]
    U.S. Supreme Court Challenge to Abortion Pills Could Boost Illegal ...
    Apr 5, 2024 · In 2019, the FDA ordered Aid Access in a letter to "immediately cease causing the introduction of these violative drugs into U.S. Commerce.
  29. [29]
    F.D.A. Will Permanently Allow Abortion Pills by Mail - The New York ...
    Dec 16, 2021 · The federal government on Thursday permanently lifted a major restriction on access to abortion pills. It will allow patients to receive the medication by mail.Missing: Aid | Show results with:Aid
  30. [30]
    FDA finalizes rule change allowing mail-order abortion pills - PBS
    Jan 3, 2023 · U.S. health officials have finalized a rule change that allows women seeking abortion pills to get them through the mail.Missing: policy | Show results with:policy
  31. [31]
    FDA expands access to mifepristone to mail-order and community ...
    Feb 7, 2022 · In 2020, FDA temporarily lifted this in-person requirement. The new change from FDA will permanently allow any certified mail-order or brick ...
  32. [32]
    [PDF] 23-235 FDA v. Alliance for Hippocratic Medicine (06/13/2024)
    Jun 13, 2024 · The medical associations claim to have standing based on their incurring costs to oppose FDA's actions. ... Several pro-life doctors and ...Missing: Aid | Show results with:Aid
  33. [33]
    Access to Abortion Medication Remains Unchanged After Ruling by ...
    Jun 13, 2024 · The Court's 9-0 ruling in Alliance for Hippocratic Medicine v. FDA allows the widely used medication, mifepristone, to remain accessible through telemedicine ...
  34. [34]
    Supreme Court allows mailed mifepristone abortion pills - STAT News
    Jun 13, 2024 · The judges unanimously rejected a challenge to an FDA decision to expand access to abortion pills by mail.<|control11|><|separator|>
  35. [35]
    Telemedicine abortion requests spiked after the Dobbs decision
    Nov 1, 2022 · There was a staggering increase in requests for abortion pills through telemedicine in the months after the Dobbs decisions.
  36. [36]
    Requests for Self-managed Medication Abortion Provided Using ...
    Nov 1, 2022 · Conflict of Interest Disclosures: Dr Gomperts reported being founder and director of Aid Access. No other disclosures were reported. Funding/ ...
  37. [37]
    Provision of Medications for Self-Managed Abortion Before and After ...
    Mar 25, 2024 · ... Aid Access showed sharp increases immediately after Dobbs, especially in states with bans. Yet beyond increased demand, little else is ...
  38. [38]
    A Patchwork of Access: Self-Managed Medication Abortion in Post ...
    Jun 21, 2024 · “Our findings demonstrate that Aid Access fills a critical gap in abortion access in the U.S. by providing a supported method of self-managed ...Missing: dropped objections shipments
  39. [39]
    Texas threatens to sue organizations and doctor for increasing ...
    Aug 20, 2025 · Attorney general Ken Paxton orders two organizations and an individual to end 'unlawful conduct' or face lawsuit.
  40. [40]
    [PDF] August 14, 2025 Via Certified Mail 7010 1060 0000 3703 4653 ...
    Aug 14, 2025 · Coeytaux: The Office of the Attorney General (OAG) has become aware that you have shipped abortion drugs into the State of Texas in violation of ...
  41. [41]
    NY attorney general will intervene in Texas abortion pill access lawsuit
    Sep 8, 2025 · “Texas has no authority in New York, and no power to impose its cruel abortion ban here.” In a statement to The Texas Tribune, Paxton called the ...Missing: August | Show results with:August
  42. [42]
    Texas to empower people to sue over abortion pills: What to know
    Sep 7, 2025 · Texas bill allowing private citizens to sue for abortion medication could limit availability and trigger legal battles in other states.<|separator|>
  43. [43]
    The Intersection of State and Federal Policies on Access to ... - KFF
    Jul 24, 2025 · Four citizen petitions have recently been filed with the FDA about mifepristone, calling for the agency to either restrict or expand access to ...
  44. [44]
    Women in states with abortion bans are the biggest users of abortion ...
    even those in states with abortion bans — thanks to shield laws ...Missing: Dobbs actions
  45. [45]
    https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00017-5/fulltext
  46. [46]
    No-Test Telehealth Medication Abortion Services Provided by US ...
    Jan 8, 2025 · Study participants included pregnant individuals up to 11 weeks gestation who completed an online consultation form on the Aid Access platform, ...
  47. [47]
    How to use the pills when more than 13 weeks pregnant? | Aid Access
    In the mouth: Put 4 pills under your tongue, or between your cheeks and gums. Hold them there for 30 minutes or until they dissolve. · In the vagina: Insert 4 ...Missing: consultation | Show results with:consultation
  48. [48]
    Communication needs of patients accessing online medication ...
    Aid Access currently offers a family physician supported online abortion service where patients communicate asynchronously with providers and service staff via ...Missing: telemedicine | Show results with:telemedicine
  49. [49]
    Inside the Online Market for Overseas Abortion Pills
    Apr 14, 2023 · Most online providers, including Aid Access and to a lesser extent Las Libres, source abortion pills from India, the world's largest ...
  50. [50]
    Aid Access
    An abortion or miscarriage treatment can be done at home with pills or in a clinic with a medical procedure. Less than 14 weeks pregnant?Abortion and Miscarriage ...About usGet an Abortion Pill Online in ...Advanced ProvisionAbortion Questions and Answers
  51. [51]
    Get an Abortion Pill Online in Texas ∙ Order Here - Aid Access
    Reliable abortion pill shipping to Texas in 1-5 days; Tracking numbers provided when the pills are mailed; Help desk support available in English and Spanish.Missing: process discreet
  52. [52]
    Abortion Support Resources - Aid Access
    The Miscarriage and Abortion Hotline provides anonymous 24/7 abortion helpline support (call or text) and medical information to people having an abortion at ...
  53. [53]
    FAQs General Questions - Aid Access
    FAQs General Questions. Pregnant and have questions about abortion pills? Aid Access provides comprehensive answers and resources for all your common questions.
  54. [54]
    Safety and effectiveness of self‐managed abortion using ...
    Feb 6, 2023 · When taking the medication, 96% were at or less than 10 weeks' gestation and 4% were more than 10 weeks. Overall, 88% (95% CI: 84.6–90.2) ...INTRODUCTION · MATERIALS AND METHODS · RESULTS · DISCUSSION
  55. [55]
    Safety and effectiveness of self-managed abortion using misoprostol ...
    Feb 6, 2023 · Overall, 88% (95% CI: 84.6-90.2) reported successfully ending their pregnancy without instrumentation intervention. Of the 568 who took the ...Missing: success | Show results with:success
  56. [56]
    Efficacy of Misoprostol Alone for First-Trimester Medical Abortion - NIH
    A systematic review published in 2007 found that the efficacy of misoprostol single-agent regimens at gestational ages ≤63 days ranged from 84% to 96%, but ...
  57. [57]
    Medication Abortion Safety and Effectiveness With Misoprostol Alone
    Oct 27, 2023 · Clinical evidence has suggested that misoprostol alone is less effective than the combined regimen (approximately 80% vs approximately 95%), and ...
  58. [58]
    The (Incomplete) Revolution in Counting Abortions
    Dec 8, 2022 · The research group found that in July and August, roughly 3,000 more pills were requested each month from Aid Access, more than double the ...<|control11|><|separator|>
  59. [59]
    https://www.ajmc.com/view/telehealth-requests-for-medication-abortion-double-post-dobbs-ruling
  60. [60]
    Characteristics of 57 506 Individuals Requesting Medication ...
    ... March 20, 2018, and March 20, 2020, 57 506 individuals requested a medication abortion from Aid Access; Table 1 shows their demographic and clinical ...
  61. [61]
    Significant Adverse Events and Outcomes After Medical Abortion
    Clinically significant adverse outcomes were rare, occurring at a rate of 16 per 10,000 medical abortions.
  62. [62]
    Analysis of Complications and Management After Self ... - NIH
    Nov 18, 2021 · The majority of the pregnant women who took MTP pills presented with serious complications in the form of bleeding, incomplete/missed abortion, and ectopic ...Missing: empirical metrics Aid
  63. [63]
    Ectopic pregnancy and unsupervised abortion pills: the hidden truth
    Jan 28, 2022 · Aim of the study was the indiscriminate use of self-consumption of abortion pills and its association with complication like ectopic pregnancy.
  64. [64]
    What if I take the abortion pill with an ectopic pregnancy?
    An abortion pill would not be effective in the case of an ectopic pregnancy because the abortion pill only expels what is inside the uterus.
  65. [65]
    Abortion Pill With An Ectopic Pregnancy: 4 Dangers
    Mar 9, 2023 · If you take the abortion pill with an ectopic pregnancy, the pregnancy can continue growing outside of the uterus. The growth of the ectopic ...
  66. [66]
    [PDF] Unsupervised Use of Abortion Pills and Its Impact on Woman's Health
    In the study done by Kumari. R et al, 11.67% women took the pills without undergoing ultrasound examination resulting in ruptured ectopic pregnancy. In the ...
  67. [67]
    Effectiveness of Self-Managed Medication Abortion Between 9 and ...
    Systematic reviews and meta-analyses of clinical trial data estimate that 94.6% of medication abortions were successful for pregnancies at 9–12 weeks 8 and ...
  68. [68]
    A Study of Incomplete Abortion Following Medical Method of ... - NIH
    Thirty percent of incomplete abortions were seen following MMA; possible reasons being self-administration or prescription by unregistered practitioners.
  69. [69]
    Mifepristone and Misoprostol for Early Pregnancy Loss and ... - AAFP
    Apr 15, 2021 · Cramping and bleeding are expected effects of the medications, with bleeding lasting an average of nine to 16 days. The adverse effects of ...
  70. [70]
    Bleeding patterns after vaginal misoprostol for treatment of early ...
    Bleeding for at least 2 weeks after vaginal misoprostol for EPF is common. Heavy bleeding is usually limited to a few days after treatment.
  71. [71]
    Medication Abortion Up to 70 Days of Gestation - ACOG
    Overall, less than 1% of patients will obtain an emergency intervention for excessive bleeding 13 14 15 32, and the need for blood transfusion is rare (0.1% of ...
  72. [72]
    PROTOCOL: Abortion and mental health outcomes: A systematic ...
    May 21, 2024 · “Women who had undergone an abortion experienced an 81% increased risk of mental health problems, and nearly 10% of the incidence of mental ...
  73. [73]
    The Evolution of “Self-Managed” Abortion: Does the Safety of ...
    Mar 1, 2022 · Researchers have documented adverse physical complications[iv], mental health complications[v], and negative impact on future pregnancies[vi], ...Missing: psychological | Show results with:psychological
  74. [74]
    Self-Managed Abortion in the United States - PMC - NIH
    Mar 7, 2023 · Evidence indicates that there is growing demand for self-managed abortion in the USA as obstacles to facility-based care increase.
  75. [75]
    Import Alert 89-08 - accessdata.fda.gov
    Divisions may detain, without physical examination, shipments of the products identified on the Red List of this alert.
  76. [76]
    Abortion pills now available by mail in US – but FDA may be ... - CNN
    Oct 23, 2018 · As a result, the FDA announced in mid-October that it was evaluating the practices of Aid Access “to assess potential violations of U.S. law.<|separator|>
  77. [77]
    Group using 'shield laws' to provide abortion care in states that ban it
    Jul 23, 2023 · Aid Access ships medication abortion to all 50 states under the protection provided to clinicians serving patients in banned states.Missing: operational kits
  78. [78]
    Texas AG Threatens Suit Over Orgs. Mailing Abortion Pills - Law360
    Aug 20, 2025 · Texas Attorney General Ken Paxton has sent cease-and-desist letters to three organizations he's accused of shipping abortion drugs to women ...<|separator|>
  79. [79]
    Meet the people sending abortion pills to places with bans - NPR
    Aug 7, 2024 · This time, Lauren got pills from Aid Access, a shield law provider similar to the MAP. "I was a little bit sketched out, I won't lie," she says.
  80. [80]
    Providers Are Still Mailing Abortion Pills to Texans
    Sep 25, 2025 · Tensions between Texas and states with laws protecting abortion providers ramps up.
  81. [81]
    Self administered medical abortion pills: evaluation of the clinical ...
    Mar 27, 2018 · Sepsis was noted in 3% patients. Emergency laprotomy was required in 11% cases. Continuation of pregnancy was reported in 13% patients.
  82. [82]
    Over-the-Counter Use of Medical Abortion Pills - ResearchGate
    Sep 3, 2023 · Conclusion: Unsupervised intake of pills increases the risk of complications like incomplete or missed abortion, sepsis, and ectopic pregnancy, ...
  83. [83]
    Is It Safe to Provide Abortion Pills over the Counter? A Study ... - NIH
    Studies comparing intake of abortion pills with medical supervision and self-administration showed that serious complications like anaemia, sepsis, failure and ...
  84. [84]
    https://www.nejm.org/doi/full/10.1056/NEJMra1908412/
  85. [85]
    The Safety and Quality of Current Abortion Methods - NCBI - NIH
    Ultrasound is not required, however, and there is no direct evidence that it improves the safety or effectiveness of the abortion (Kaneshiro et al., 2011; NAF, ...
  86. [86]
    New Study Shows Medication Abortion Without Ultrasound To Be Safe
    Jun 24, 2024 · Ultrasound is not necessary for medication abortion, and patients do equally well whether they are seen in person or via telehealth, ...Missing: informed consent
  87. [87]
    Managing Abortion Pain Experienced by Remote Telehealth Patients
    Feb 1, 2025 · Although telemedicine abortion safety has been questioned because physicians at a distance are generally unable to attend as quickly as those in ...Missing: oversight | Show results with:oversight
  88. [88]
    The Impact of Self-Administered Abortion Pills: An Observational ...
    May 14, 2025 · Ectopic pregnancy is a contraindication to medical abortion, and misdiagnosis or delayed diagnosis due to lack of pre-abortion assessment can ...
  89. [89]
    Effectiveness and safety of telehealth medication abortion in the USA
    Feb 15, 2024 · Telehealth medication abortion is effective, safe and comparable to published rates of in-person medication abortion care.
  90. [90]
    Determinants of Unsupervised Medical Termination of Pregnancy ...
    Nov 24, 2023 · However, unsupervised MTP pill use is on the rise, posing serious health risks. Unsafe abortions remain a global public health concern, with ...
  91. [91]
    The Pro-Life View on Abortion - Americans United for Life
    At the heart of the pro-life view is the belief in the sanctity of human life. In opposing abortion, we acknowledge the humanity of the child in the womb.<|separator|>
  92. [92]
    Abortion Drugs at the Supreme Court - SBA Pro-Life America
    Doctors, who have been witnessing the harm of abortion drugs to women and girls, are asking the Court to hold the FDA accountable for failing its duty to ...
  93. [93]
    Fact Sheet: Risks and Complications of Chemical Abortion
    Jul 19, 2022 · A key analysis of abortion pill-related adverse events submitted to the FDA shows significant underreporting. Planned Parenthood independently ...
  94. [94]
    Fact Sheet: Three Problems with the FDA's Abortion Drugs ...
    Mar 22, 2024 · The FDA has missed a large percentage of all complications. Even before the FDA weakened the adverse event reporting requirements, data was severely lacking.
  95. [95]
    Abortion Drug Facts - Lozier Institute
    U.S. abortion data is generally very poor. A key analysis of abortion-drug-related adverse events submitted to the FDA shows significant underreporting – and ...
  96. [96]
    INJUSTICE: Pro-Abortion Misinformation Leads to Two Women's ...
    Sep 18, 2024 · The pro-life community has spent years raising the alarm about abortion drugs that send one in 25 women to the emergency room. Specifically, we' ...
  97. [97]
    Susan B. Anthony Pro-Life America
    SBA Pro-Life America fights for the election of women and men who will fight for life. We fight for laws that safeguard the innocent, and we develop ...About · 2024 Election Report · Pro-Life Women's Caucus · Latest Pro-Life News
  98. [98]
    Telehealth has changed the abortion landscape, study says | STAT
    Aug 11, 2025 · By the end of 2024, a monthly average of more than 12,000 medication abortions were provided to patients in states with bans or telehealth ...
  99. [99]
    Texas Aimed to Ban Abortion Pills—But the Law Has Had Little Effect
    Mar 8, 2022 · Another UT-Austin study found that Aid Access received an average of more than 1,100 requests per month from Texas for abortion medication from ...
  100. [100]
    Travel time, costs for abortions increased after state bans ...
    Jul 16, 2025 · Travel time for residents from abortion-ban states increased from 2.8 hours to 11.3 hours, compared with abortion access before a ban, and ...Missing: wait blue
  101. [101]
    Advance Provision of Mifepristone and Misoprostol via Online ... - NIH
    Jan 2, 2024 · After the Dobbs leak, the mean weekly rate increased from 0.4 to 3.5 per 100 000 reproductive-age women in states where an abortion ban was ...
  102. [102]
    Advance Provision of Mifepristone and Misoprostol via Online ...
    Jan 2, 2024 · During the study period, Aid Access received 48 404 advance provision requests. Compared with those requesting self-managed abortion, a higher ...<|separator|>
  103. [103]
    Women in the US Are Now Stockpiling Abortion Pills - WIRED
    Jan 2, 2024 · White women make up 70 percent of Aid Access' advance provision requests, compared to 39 percent of requests for abortion pills for immediate ...Missing: metrics | Show results with:metrics
  104. [104]
    Threats to medication abortion access drive U.S. women to stockpile ...
    Jan 2, 2024 · Aid Access received about 48,400 requests from across the U.S. for so-called “advance provision” from September 2021 through April 2023.Missing: metrics | Show results with:metrics
  105. [105]
    U.S. Clinicians Can Now Mail Abortion Pills to States Banning ...
    Jul 24, 2023 · Aid Access served people in all 50 states, but since telemedicine abortion was not allowed in the United States at the time, clinicians had ...Missing: targeting users direct
  106. [106]
    Despite Bans, Number of Abortions in the United States Increased in ...
    Mar 19, 2024 · Increased financial support post-Dobbs—particularly from abortion funds—was a critical source of funding for people in ban states and may have ...
  107. [107]
    Conservatives targeting abortion pills look beyond the Supreme Court
    Mar 27, 2024 · Supreme Court case is one of many tools elected officials and activists are using to try to cut off access to the drugs.
  108. [108]
    With lawsuits and legislation, Texas Republicans take aim at ...
    Jan 7, 2025 · Wells said they take seriously any legislation that might further restrict access to abortion in states like Texas. But she said even if all the ...
  109. [109]
    The Doctors Risking Everything to Offer Abortions Across State Lines
    Oct 5, 2022 · State shield laws for abortion undermine basic premises of interstate cooperation. One state effectively throws a wrench into the enforcement of ...
  110. [110]
    FDA preemption of conflicting state drug regulation and the looming ...
    Mar 15, 2023 · ... clinical study data; the fact that FDA had followed a particular ... Aid Access, Hey Jane, and Abortion on Demand to send the drug ...
  111. [111]
    https://jamanetwork.com/journals/jama/fullarticle/2840574
  112. [112]
    Abortion Pill Access Threat Renewed by Red States, Federal Study
    Sep 24, 2025 · The litigation stems back to 2022, when a physicians group sued the FDA over decisions such as allowing dispensing without in-person visits and ...
  113. [113]
    Self-managed abortions increased by about 26000 after Dobbs ...
    Mar 26, 2024 · Self-managed abortions rose by more than 26,000 in the six months after the U.S. Supreme Court overturned Roe v. Wade nearly two years ago, ...Missing: success | Show results with:success
  114. [114]
    The effects of post-Dobbs abortion bans on fertility - ScienceDirect.com
    The results indicate that states with abortion bans experienced an average increase in births of 2.3 percent relative to if no bans had been enforced.
  115. [115]
    Changes in Abortion Access, Travel, and Costs Since the ...
    Sep 10, 2025 · Mean travel time was longer, from 2.8 hours to 11.3 hours, and the proportion staying overnight was greater (5% vs 58%) after a ban (Table 2).